Apr 15, 2025
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
Mar 26, 2025
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Mar 26, 2025
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
Jan 28, 2025
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Nov 26, 2024
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
Nov 13, 2024
Leap Therapeutics Reports Third Quarter 2024 Financial Results
Sep 30, 2024
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Aug 12, 2024
Leap Therapeutics Reports Second Quarter 2024 Financial Results
May 13, 2024
Leap Therapeutics Reports First Quarter 2024 Financial Results
Mar 18, 2024
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Jan 03, 2024
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 02, 2024
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
Jan 06, 2021
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
Jan 04, 2021
Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Dec 22, 2020
Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research
Nov 23, 2020
Leap Therapeutics to Participate at Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 10, 2020
Leap Therapeutics to Present at Stifel 2020 Healthcare Conference
Nov 09, 2020
Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference
Oct 15, 2020
Leap Therapeutics to Present Esophagogastric Cancer Data at SITC 2020 Annual Meeting
Sep 24, 2020
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer